Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel L Price

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 14, 2022
Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell CarcinomaDavid M Routman, Sunil Kumar, Bisham S Chera, et al.
International Journal of Radiation Oncology, Biology, Physics|December 28, 2020
Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the OropharynxMark R Waddle, Daniel J Ma, Sue L Visscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell CarcinomaDaniel J Ma, Katharine A Price, Eric J Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2019
Reply to A.S. GardenDaniel J Ma, Katharine A Price, Eric J Moore, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 22, 2025
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical TrialDavid M Routman, Kathryn M Van Abel, Katharine A Price, et al.
Oral Oncology|September 21, 2023
Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary centerChadi N Abdel-Halim, Thomas J O'Byrne, Jeffrey P Graves, et al.
Oral Oncology|May 18, 2025
Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinomaBrennan Olson, Aaron Bogan, Chadi N Abdel-Halim, et al.
JAMA Network Open|May 18, 2026
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal CancerCecelia M Hidalgo, Aaron W Bogan, Katelyn S Rourk, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
International Journal of Radiation Oncology, Biology, Physics|February 14, 2022
Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell CarcinomaDavid M Routman, Sunil Kumar, Bisham S Chera, et al.
International Journal of Radiation Oncology, Biology, Physics|December 28, 2020
Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the OropharynxMark R Waddle, Daniel J Ma, Sue L Visscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2019
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell CarcinomaDaniel J Ma, Katharine A Price, Eric J Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2019
Reply to A.S. GardenDaniel J Ma, Katharine A Price, Eric J Moore, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Nature Communications|February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trialTina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 22, 2025
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma: A Secondary Analysis of the DART Phase 3 Randomized Clinical TrialDavid M Routman, Kathryn M Van Abel, Katharine A Price, et al.
Oral Oncology|September 21, 2023
Patterns and distribution of regional nodal involvement and recurrence in a surgically treated oropharyngeal squamous cell carcinoma cohort at a tertiary centerChadi N Abdel-Halim, Thomas J O'Byrne, Jeffrey P Graves, et al.
Oral Oncology|May 18, 2025
Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinomaBrennan Olson, Aaron Bogan, Chadi N Abdel-Halim, et al.
JAMA Network Open|May 18, 2026
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal CancerCecelia M Hidalgo, Aaron W Bogan, Katelyn S Rourk, et al.
Pageof 15